Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside
Ana Villegas, Fernando A Gonzalez, Leopoldo Llorente, Santiago RedondoService of Hematology and Hemotherapy, Hospital Clinico Universitario San Carlos, Madrid, SpainAbstract: Atherosclerotic cardiovascular disease is the leading cause of death and a major part of its pathophysiology remains obscure....
Guardado en:
Autores principales: | Ana Villegas, Fernando A Gonzalez, Leopoldo Llorente, Santiago Redondo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1ef7c8f9ebc54c64bed1ad8d588800f8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Oncolytic Virotherapy: From Bench to Bedside
por: Ludi Yang, et al.
Publicado: (2021) -
Inflammation, Bone Healing and Osteonecrosis: From Bedside to Bench
por: Goodman SB, et al.
Publicado: (2020) -
Clinical utility of asthma biomarkers: from bench to bedside
por: Vijverberg SJH, et al.
Publicado: (2013) -
Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside
por: Zatsepin TS, et al.
Publicado: (2016) -
Antineutrophil cytoplasmic antibodies-associated glomerulonephritis: From bench to bedside
por: Yong-Xi Chen, et al.
Publicado: (2018)